Deepmatter Group PLC (LON: DMTR) have seen their shares rally on Monday morning after the firm announced a pharmaceutical technology collaboration.
Deepmatter platform transforms chemistry into code. It uses Artificial Intelligence (AI) and Machine Learning (ML) to make better molecules and provide insights never before available.
Digitized chemistry enhances reproducibility and increases productivity. The contextualized data generated by deepmatter provides greater access to high fidelity data and informs and improves better outcomes.
Deepmatter shares rallied after the firm said that it will be collaborating with giant AstraZeneca PLC (LON: AZN) in a digital technology venture, designed to speed up the drug delivery process.
AstraZeneca is a FTSE100 and announced that it had received received marketing authorization from China’s National Medical Products Administration for their Lynparza drug with partner Merck & Co just last week, which won shareholder appetite.
Additionally, the firm in November said that it had made progress in in a developing a new Anaemia drug which the firm has been working on over the last few months.
In this update, a collaboration deal with with US based FibroGen for Roxadustat was announced which saw the firms shares in green.
Today Deepmatter, will work with AstraZeneca on their DigitalGlassware platform, which enables chemists to share the details of their experiments from anywhere and in real-time.
Michael Kossenjans, an associate director at Astra’s Discovery Sciences, Research & Development unit, said: “Our goal is to transform drug design using innovative digital technologies in combination with automation and artificial intelligence. To get potential new medicines to patients faster, we need to reduce the cycle time for lead identification and optimisation and look forward to working with DeepMatter to assess the potential of DigitalGlassware to help with this.”
DeepMatter Chief Executive added: “We’ve been impressed with the automated chemistry platforms developed at AstraZeneca sites for autonomous delivery of new lead series. We see an opportunity to draw together knowledge from the DigitalGlassware platform to enable machine learning and artificial intelligence technologies to increase the certainty of producing a high quality and choice of candidate drug molecules.
“We look forward to progressing this exciting collaboration over the coming months as we continue to maximise the potential of the DigitalGlassware platform.”
DeepMatter explained: “Displayed in real time, the data can be interrogated using multiple views, enabling the analysis of reaction runs and the re-playing of syntheses. By capturing in-situ chemical data alongside the experimental intent, observations and outcomes, it is expected that machine learning and artificial algorithms could yield cost and time savings whilst also providing novel insights into chemistry.”
Shares of Deepmatter surged 43.9% to 2p. 9/12/19 11:17BST.
